Short Interest in TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Decreases By 41.0%

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) was the target of a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 38,300 shares, a decline of 41.0% from the October 31st total of 64,900 shares. Based on an average daily volume of 1,230,000 shares, the short-interest ratio is currently 0.0 days.

TC Biopharm Stock Down 6.7 %

TCBP traded down $0.04 during midday trading on Friday, hitting $0.56. The company’s stock had a trading volume of 452,118 shares, compared to its average volume of 507,828. TC Biopharm has a 52-week low of $0.44 and a 52-week high of $80.00. The firm has a 50-day moving average price of $2.94 and a two-hundred day moving average price of $6.14. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 1.31.

TC Biopharm Company Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.